Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) closed the day trading at $9.66 down -0.82% from the previous closing price of $9.74. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 2.56 million shares were traded. BCRX stock price reached its highest trading level at $9.81 during the session, while it also had its lowest trading level at $9.61.
Ratios:
For a better understanding of BCRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.88 and its Current Ratio is at 2.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 29, 2025, initiated with a Overweight rating and assigned the stock a target price of $20.
On February 25, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 13 ’24 when Hutson Nancy J sold 7,000 shares for $7.54 per share. The transaction valued at 52,780 led to the insider holds 86,638 shares of the business.
Hutson Nancy J bought 7,000 shares of BCRX for $52,584 on Dec 13 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 2021355008 and an Enterprise Value of 2555555584. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.01. Its current Enterprise Value per Revenue stands at 5.076 whereas that against EBITDA is 68.197.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.08, which has changed by 0.5631068 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.00. The 50-Day Moving Average of the stock is -1.41%, while the 200-Day Moving Average is calculated to be 16.84%.
Shares Statistics:
Over the past 3-months, BCRX traded about 4.50M shares per day on average, while over the past 10 days, BCRX traded about 3334910 shares per day. A total of 209.21M shares are outstanding, with a floating share count of 200.37M. Insiders hold about 4.24% of the company’s shares, while institutions hold 84.28% stake in the company. Shares short for BCRX as of 1749772800 were 23076302 with a Short Ratio of 5.13, compared to 1747267200 on 20977946. Therefore, it implies a Short% of Shares Outstanding of 23076302 and a Short% of Float of 11.07.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Biocryst Pharmaceuticals Inc (BCRX) is currently under the scrutiny of 6.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.05, with high estimates of $0.13 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.35 and $0.0 for the fiscal current year, implying an average EPS of $0.19. EPS for the following year is $0.53, with 7.0 analysts recommending between $0.85 and $0.26.
Revenue Estimates
10 analysts predict $149.53M in revenue for the current quarter. It ranges from a high estimate of $156.02M to a low estimate of $143.07M. As of the current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $109.33MFor the next quarter, 10 analysts are estimating revenue of $156.51M. There is a high estimate of $158.6M for the next quarter, whereas the lowest estimate is $153.75M.
A total of 10 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $629.89M, while the lowest revenue estimate was $600.13M, resulting in an average revenue estimate of $613.79M. In the same quarter a year ago, actual revenue was $450.71MBased on 10 analysts’ estimates, the company’s revenue will be $698.35M in the next fiscal year. The high estimate is $738.79M and the low estimate is $656.32M.
